Although the application of various tyrosine kinase inhibitors (TKIs) could prolong the survival time of NSCLC patients who had epidermal growth factor receptor (EGFR) mutation, patients with wild-type EGFR in advanced NSCLC are still not optimistic [3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.